Cover Image
市場調查報告書

Diurnal Ltd的產品平台分析

Diurnal Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 319970
出版日期 內容資訊 英文 26 Pages
訂單完成後即時交付
價格
Back to Top
Diurnal Ltd的產品平台分析 Diurnal Limited - Product Pipeline Review - 2015
出版日期: 2015年11月30日 內容資訊: 英文 26 Pages
簡介

Diurnal Ltd是總公司位於英國的製藥企業,正在進行副腎功能衰竭,性腺功能降低症,類風濕性關節炎,甲狀腺機能低下症等領域之藥物的開發。開發中產品有先天性副腎功能衰竭治療藥的Chronocort(皮質醇補充藥),用於緩和類風濕性關節炎症狀的Rheumacort等。

本報告提供Diurnal Ltd的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,加上最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Diurnal Ltd的基本資料

  • Diurnal Ltd概要
  • 主要資訊
  • 企業資料

Diurnal Ltd:R&D概要

  • 主要的治療範圍

Diurnal Ltd:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 開發中產品/聯合治療模式

Diurnal Ltd:開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Diurnal Ltd:藥物簡介

  • hydrocortisone MR
  • hydrocortisone IR
  • (triiodothyronine + thyroxine)
  • Rheumacort
  • testosterone

Diurnal Ltd:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Diurnal Ltd:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07825CDB

Summary

Global Markets Direct's, 'Diurnal Limited - Product Pipeline Review - 2015', provides an overview of the Diurnal Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Diurnal Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Diurnal Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Diurnal Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Diurnal Limited's pipeline products

Reasons to buy

  • Evaluate Diurnal Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Diurnal Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Diurnal Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Diurnal Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Diurnal Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Diurnal Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Diurnal Limited Snapshot
    • Diurnal Limited Overview
    • Key Information
    • Key Facts
  • Diurnal Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Diurnal Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Diurnal Limited - Pipeline Products Glance
    • Diurnal Limited - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Diurnal Limited - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Diurnal Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Diurnal Limited - Drug Profiles
    • hydrocortisone IR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hydrocortisone MR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (liothyronine + levothyroxine)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • testosterone
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Diurnal Limited - Pipeline Analysis
    • Diurnal Limited - Pipeline Products by Target
    • Diurnal Limited - Pipeline Products by Route of Administration
    • Diurnal Limited - Pipeline Products by Molecule Type
    • Diurnal Limited - Pipeline Products by Mechanism of Action
  • Diurnal Limited - Recent Pipeline Updates
  • Diurnal Limited - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Diurnal Limited, Key Information
  • Diurnal Limited, Key Facts
  • Diurnal Limited - Pipeline by Indication, 2015
  • Diurnal Limited - Pipeline by Stage of Development, 2015
  • Diurnal Limited - Monotherapy Products in Pipeline, 2015
  • Diurnal Limited - Combination Treatment Modalities in Pipeline, 2015
  • Diurnal Limited - Phase III, 2015
  • Diurnal Limited - Phase I, 2015
  • Diurnal Limited - Preclinical, 2015
  • Diurnal Limited - Pipeline by Target, 2015
  • Diurnal Limited - Pipeline by Route of Administration, 2015
  • Diurnal Limited - Pipeline by Molecule Type, 2015
  • Diurnal Limited - Pipeline Products by Mechanism of Action, 2015
  • Diurnal Limited - Recent Pipeline Updates, 2015

List of Figures

  • Diurnal Limited - Pipeline by Top 10 Indication, 2015
  • Diurnal Limited - Pipeline by Stage of Development, 2015
  • Diurnal Limited - Monotherapy Products in Pipeline, 2015
  • Diurnal Limited - Pipeline by Top 10 Target, 2015
  • Diurnal Limited - Pipeline by Top 10 Route of Administration, 2015
  • Diurnal Limited - Pipeline by Top 10 Molecule Type, 2015
  • Diurnal Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top